SearchBar Icon

Global Next-Generation Antibody Therapeutics Market (Size of $1,328 million in 2014) to Witness 44% CAGR during 2015 – 2020

Published Date:   August 2015

The global next-generation antibody therapeutics market was valued at $1,328.3 million in 2014 and it is expected to grow at a CAGR of about 44% during the period 2015 - 2020. The global next-generation antibody therapeutics market is growing due to increasing popularity of antibody-drug conjugate (ADC) and increasing number of collaborations for R&D in next-generation antibody therapeutics. In addition, growing prevalence of chronic diseases and increase in research and development investments by various organizations for production of improved products further encourages the growth of global next-generation antibody therapeutics market. Furthermore, increase in healthcare expenditure and technological advancements in antibody therapeutics have led to the development of more efficient antibody therapeutics, which is resulting in increased demand for next-generation antibody therapeutics.

Explore report description with detailed TOC at:

Based on technology, the Fc Engineered Antibodies market is expected to witness the highest growth (CAGR of 11%) during the forecast period. Among the therapeutic areas, the oncology segment led the global next-generation antibody therapeutics market in 2014, with the largest market size, but the autoimmune/inflammatory is expected to see the fastest growth of 46.4% CAGR, during the period 2015 – 2020.

The information and data in the publication “Global Next-Generation Antibody Therapeutics Market Size, Share, Development, Growth and Demand Forecast to 2020” represent the research and analysis of data from various primary and secondary sources. The bottom-up approach has been used to calculate the global EHR systems market by type and by therapeutic area. The market numbers for countries are obtained through top-down approach. P&S Intelligence analysts and consultants interact with leading companies of the concerned domain to substantiate every single data presented in this report. The company bases its primary research on discussions with prominent professionals and analysts in the industry, aided by informed and detailed online and offline research.

Governments of various countries are involved in taking initiatives for improving healthcare facilities, and making next-generation antibody therapeutics affordable. This is increasing the demand for next-generation antibody therapeutics. The increasing global gross domestic product (GDP) and growing healthcare expenditure have created a positive impact on the growth of the next-generation antibody therapeutics market. Also, in comparison to traditional antibodies, the next-generation antibody therapeutics is more effective in the treatment of various diseases, such as cancer, autoimmune disorders, and inflammatory diseases. This is attracting various pharmaceutical and biotechnology companies to increase their investment in the R&D of next-generation antibody therapeutics.

However, certain restraints such as high cost of next-generation antibody therapeutics, stringent regulatory requirements and time-consuming approval process for new drugs are hindering the market growth. North America next-generation antibody therapeutics market is expected to witness the fastest growth of CAGR 46.2% globally, during the period 2015 – 2020.

The key companies operating in the global next-generation antibody therapeutics market include Seattle Genetics Inc., F. Hoffmann-La Roche Ltd, ImmunoGen Inc., Pfizer Inc., Amgen Inc., Biogen, Kyowa Hakko Kirin Co. Ltd., Bristol-Myers Squibb Company, Xencor Inc., AstraZeneca PLC., Dyax Corp., Takeda Pharmaceuticals Company Limited and Bayer AG.


Next-Generation antibody therapeutics market by therapeutic area

  • Oncology
  • Autoimmune/Inflammatory

Next-Generation antibody therapeutics market by technology

  • Antibody Drug Conjugates (ADCs)
  • Bispecific Antibodies (BsAbs)
  • Fc Engineered Antibodies
  • Antibody Fragments and Antibody-like Proteins (AF & ALPs)
  • Biosimilar Antibody (Ab) products


  • North America – U.S., and Rest of North America
  • Europe – Germany, France, U.K., and Rest of Europe
  • Asia-Pacific – Japan, and Rest of Asia-Pacific
  • Rest of the World (RoW)